Abstract
With continued advances in gene sequencing technologies comes the need to develop better tools to understand which mutations cause disease. Here we validate structure-based network analysis (SBNA)1, 2 in well-studied human proteins and report results of using SBNA to identify critical amino acids that may cause retinal disease if subject to missense mutation. We computed SBNA scores for genes with high-quality structural data, starting with validating the method using 4 well-studied human disease-associated proteins. We then analyzed 47 inherited retinal disease (IRD) genes. We compared SBNA scores to phenotype data from the ClinVar database and found a significant difference between benign and pathogenic mutations with respect to network score. Finally, we applied this approach to 65 patients at Massachusetts Eye and Ear (MEE) who were diagnosed with IRD but for whom no genetic cause was found. Multivariable logistic regression models built using SBNA scores for IRD-associated genes successfully predicted pathogenicity of novel mutations, allowing us to identify likely causative disease variants in 37 patients with IRD from our clinic. In conclusion, SBNA can be meaningfully applied to human proteins and may help predict mutations causative of IRD.
Competing Interest Statement
E.J.R. and G.D.G. have filed patent application PCT/US2021/028245.
Funding Statement
B.M.H. is supported by award number T32GM144273 from the National Institute of General Medical Sciences and award number F30AI160908 from the National Institute of Allergy and Infectious Diseases. E.J.R. is supported by award number K12EY016335 from the National Eye Institute and the Massachusetts Lions Eye Research Fund. The funding organizations had no role in design or conduct of this research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of Mass General Brigham gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding: B.M.H. is supported by award number T32GM144273 from the National Institute of General Medical Sciences and award number F30AI160908 from the National Institute of Allergy and Infectious Diseases. E.J.R. is supported by award number K12EY016335 from the National Eye Institute and the Massachusetts Lions Eye Research Fund. The funding organizations had no role in design or conduct of this research.
Disclosure statement: E.J.R. and G.D.G. have filed patent application PCT/US2021/028245.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
